{
    "Trade/Device Name(s)": [
        "GlucoSure Link Blood Glucose Monitoring System"
    ],
    "Submitter Information": "Apex Biotechnology Corp.",
    "510(k) Number": "K212140",
    "Predicate Device Reference 510(k) Number(s)": [
        "K102037"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "August 25, 2022",
    "Summary Letter Received Date": "May 16, 2022",
    "Submission Date": "May 13, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "GlucoSure Link Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Meter",
        "Test Strip"
    ],
    "Document Summary": "FDA 510(k) summary for GlucoSure Link Blood Glucose Monitoring System, a home-use self-testing system for quantitative measurement of glucose in capillary whole blood.",
    "Indications for Use Summary": "For quantitative measurement of glucose in fresh capillary whole blood from fingertips, forearm, or palm by people with diabetes at home for self-testing as an aid to monitor diabetes control; not for diagnosis, screening, or use on neonates.",
    "fda_folder": "Clinical Chemistry"
}